Clinical Trial Update: A One-year Safety Study of Flibanserin to Treat Pre-Menopausal Women With Hypoactive Sexual Desire Disorder (HSDD). [Phase 3]

View source ↗

Summary

A Phase 3 one-year safety study of flibanserin for hypoactive sexual desire disorder in pre-menopausal women was terminated; results were posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypoactive Sexual Desire Disorder
• Sexual Dysfunction

Drugs mentioned

• ADDYI (flibanserin)

Snippet

Sponsor: Sprout Pharmaceuticals, Inc | Conditions: Sexual Dysfunctions, Psychological | Phase 3 | Status: TERMINATED | Results posted: 2014-06-13